Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
901 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02488330 | An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | completed | Phase 3 | 12 | Hoffmann-La RocheINDUSTRY | 8 | Jul 23, 2019 | clinicaltrials |
| NCT03092739 | A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens | completed | — | 184 | Hoffmann-La RocheINDUSTRY | 6 | Jul 23, 2019 |
| NCT03558490 | A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment(ZEMY) | completed | Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 1 | Jul 22, 2019 | clinicaltrials |
| NCT03362723 | A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors | completed | Phase 1 | 48 | Hoffmann-La RocheINDUSTRY | 2 | Jun 19, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | completed | Phase 2 | 152 | Hoffmann-La RocheINDUSTRY | 18 | Jun 3, 2019 | clinicaltrials |
| NCT01910181 | A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | completed | Phase 1 | 46 | Hoffmann-La RocheINDUSTRY | 1 | May 29, 2019 | clinicaltrials |
| NCT02674009 | Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)(NIELS) | completed | — | 67 | Hoffmann-La RocheINDUSTRY | 1 | May 13, 2019 | clinicaltrials |
| NCT03052569 | Expanded Access to RXDX-105 for Cancers With RET Alterations | no longer available | — | — | Hoffmann-La RocheINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03066661 | Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions | no longer available | — | — | Hoffmann-La RocheINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01877811 | Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors | completed | Phase 1 | 143 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2019 | clinicaltrials |
| NCT02548390 | Study of Intravenous RXDX-107 in Patients With Solid Tumors | terminated | Phase 1 | 70 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03454243 | Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors(TITAN) | terminated | Early Phase 1 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03399643 | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)(Announce) | terminated | — | 22 | Hoffmann-La RocheINDUSTRY | 1 | Apr 19, 2019 | clinicaltrials |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | terminated | Phase 3 | 1,418 | Hoffmann-La RocheINDUSTRY | 29 | Apr 12, 2019 | clinicaltrials |
| NCT02666261 | A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany | completed | — | 15,000 | Hoffmann-La RocheINDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01555762 | An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE) | completed | — | 402 | Hoffmann-La RocheINDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 | clinicaltrials |
| NCT01588990 | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer(ASCENT) | completed | Phase 4 | 128 | Hoffmann-La RocheINDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03139513 | A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])(MELANIS) | completed | — | 200 | Hoffmann-La RocheINDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT00545714 | A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 86 | Hoffmann-La RocheINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01788995 | BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer | completed | — | 63 | Hoffmann-La RocheINDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01987505 | MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma | completed | Phase 3 | 140 | Hoffmann-La RocheINDUSTRY | 1 | Dec 26, 2018 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT01069627 | A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 1 | Dec 6, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT03153163 | Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer | completed | Phase 1 | 11 | Hoffmann-La RocheINDUSTRY | 1 | Nov 23, 2018 | clinicaltrials |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 15, 2018 | clinicaltrials |
| NCT02458651 | Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China | completed | — | 1,378 | Hoffmann-La RocheINDUSTRY | 1 | Nov 9, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT01260181 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02913443 | A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC) | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Oct 19, 2018 | clinicaltrials |
| NCT01178086 | A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | — | 681 | Hoffmann-La RocheINDUSTRY | 1 | Oct 5, 2018 | clinicaltrials |
| NCT01688206 | A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 132 | Hoffmann-La RocheINDUSTRY | 3 | Oct 5, 2018 | clinicaltrials |
| NCT01174563 | A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01863693 | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1) | completed | — | 300 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02019277 | A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer(SAPPHIRE) | completed | Phase 3 | 50 | Hoffmann-La RocheINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01310036 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2018 | clinicaltrials |
| NCT02761642 | A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy | completed | Phase 2 | 200 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2018 | clinicaltrials |
| NCT02305615 | An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)(AVACONT) | completed | — | 300 | Hoffmann-La RocheINDUSTRY | 1 | Aug 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials